{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010540","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.212868+00:00","generated_at":"2026-05-16T10:50:22.994681+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apellis reports preliminary 2025 U.S. net product revenues of $689M; cash $466M; SYFOVRE injections up 17%","bullets":["Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.","SYFOVRE total injection demand grew 17% YoY; ~60% market share in geographic atrophy; prefilled syringe submission planned 1H 2026.","EMPAVELI C3G/IC-MPGN launch: 267 patient start forms in 2025, >5% market penetration; 95% payer coverage.","Cash and cash equivalents ~$466M at Dec 31, 2025; company expects to fund operations to profitability.","Pivotal trials initiated for EMPAVELI in FSGS and DGF; IND for APL-9099 (FcRn) planned 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010540","json":"https://secwatch.observer/filing/0001193125-26-010540.json","markdown":"https://secwatch.observer/filing/0001193125-26-010540.md","text":"https://secwatch.observer/filing/0001193125-26-010540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526010540/0001193125-26-010540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526010540/d19666d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:22.994681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}